Intellia Therapeutics Reports Positive Phase 3 Results For HAE Gene Therapy; Stock Up
Summary
Intellia Therapeutics, Inc. (NTLA) on Monday reported positive topline results from its Phase 3 HAELO trial of lonvo-z, a CRISPR-based gene editing therapy for ...
Description
Intellia Therapeutics, Inc. (NTLA) on Monday reported positive topline results from its Phase 3 HAELO trial of lonvo-z, a CRISPR-based gene editing therapy for ...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source